Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Himanshu Naik"'
Autor:
Catharina G. Faber, Nadine Attal, Giuseppe Lauria, Robert H. Dworkin, Roy Freeman, Katherine T. Dawson, Helen Finnigan, Amirhossein Hajihosseini, Himanshu Naik, Michael Serenko, Christopher J. Morris, Mona Kotecha
Publikováno v:
EClinicalMedicine, Vol 59, Iss , Pp 101971- (2023)
Summary: Background: No pharmacological treatments are specifically indicated for painful small fibre neuropathy (SFN). CONVEY, a phase 2 enriched-enrolment study, evaluated the efficacy and safety of vixotrigine, a voltage- and use-dependent sodium
Externí odkaz:
https://doaj.org/article/98dd54c83e884b6a959fad1b27b55fcf
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 4, Pp 1272-1279 (2021)
Neuropathic pain affects ~ 6.9–10% of the general population and leads to loss of function, anxiety, depression, sleep disturbance, and impaired cognition. Here, we report the safety, tolerability, and pharmacokinetics of a voltage‐dependent and
Externí odkaz:
https://doaj.org/article/d286187d2d1940e9bba14ebcd444665b
Autor:
Yuan Zhao, Kun Chen, Nancy Ramia, Sangeeta Sahu, Achint Kumar, Maria L. Naylor, Li Zhu, Himanshu Naik, Cherié L. Butts
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 14 (2021)
Background: Peginterferon beta-1a administered every 2 weeks via subcutaneous (SC) injection is approved to treat adult patients with relapsing-remitting multiple sclerosis (RRMS) and relapsing forms of multiple sclerosis (RMS). However, associated i
Externí odkaz:
https://doaj.org/article/e34c67943f41454384c25cf085c4bbfd
Publikováno v:
PLoS ONE, Vol 8, Iss 6, p e66422 (2013)
Peginesatide (OMONTYS®) is an erythropoiesis-stimulating agent that was indicated in the United States for the treatment of anemia due to chronic kidney disease in adult patients on dialysis prior to its recent marketing withdrawal by the manufactur
Externí odkaz:
https://doaj.org/article/4b69e4dfd05b48daa768fea949805b53
Publikováno v:
Kidney Research and Clinical Practice, Vol 31, Iss 2, p A60 (2012)
Peginesatide is an erythropoiesis stimulating agent (ESA) being developed for the treatment of anemia due to chronic kidney disease in dialysis patients. The purpose of this analysis was to develop a population PK-PD model to characterize time-course
Externí odkaz:
https://doaj.org/article/af57e6dfe23f4c3fba7e4de44c428fc0
Publikováno v:
Clinical Drug Investigation. 42:829-837
Vixotrigine is a voltage-dependent and use-dependent sodium channel blocker in development for the treatment of neuropathic pain. Metabolism of vixotrigine is primarily through glucuronidation, resulting in the major M13 metabolite. Two additional ma
Autor:
Victoria P, Werth, Richard A, Furie, Juanita, Romero-Diaz, Sandra, Navarra, Kenneth, Kalunian, Ronald F, van Vollenhoven, Filippa, Nyberg, Benjamin H, Kaffenberger, Saira Z, Sheikh, Goran, Radunovic, Xiaobi, Huang, George, Clark, Hua, Carroll, Himanshu, Naik, Francois, Gaudreault, Adam, Meyers, Catherine, Barbey, Cristina, Musselli, Nathalie, Franchimont, Victoria, Werth
Publikováno v:
New England journal of medicine, 387(4), 321-3313. Massachussetts Medical Society
New England Journal of Medicine, 387(4), 321-3313. Massachussetts Medical Society
the LILAC Trial Investigators 2022, ' Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus ', New England Journal of Medicine, vol. 387, no. 4, pp. 321-3313 . https://doi.org/10.1056/NEJMoa2118024
New England Journal of Medicine, 387(4), 321-3313. Massachussetts Medical Society
the LILAC Trial Investigators 2022, ' Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus ', New England Journal of Medicine, vol. 387, no. 4, pp. 321-3313 . https://doi.org/10.1056/NEJMoa2118024
Blood dendritic cell antigen 2 (BDCA2) is a receptor that is exclusively expressed on plasmacytoid dendritic cells, which are implicated in the pathogenesis of lupus erythematosus. Whether treatment with litifilimab, a humanized monoclonal antibody a
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics. 46:395-404
Vixotrigine is a voltage and use dependent sodium channel blocker currently under development for treatment of various neuropathic pain indications. The objective of this work was to develop a population pharmacokinetic model and assess effects of va
Autor:
Mihály Hajós, Yuri A. Kuryshev, Alissende Sers, Bruno Buisson, Christopher A Hinckley, Himanshu Naik, Alexander Barre
Publikováno v:
Molecular Pharmacology. 99:49-59
Voltage-gated sodium channels (Navs) are promising targets for analgesic and antiepileptic therapies. Although specificity between Nav subtypes may be desirable to target specific neural types, such as nociceptors in pain, many broadly acting Nav inh
Autor:
Davina Owen, Kevin Gunn, Himanshu Naik, Francois Rugiero, Giuseppe Alvaro, Gerard M. P. Giblin, Dominique Derjean, David R Witty, Valerie Morisset, Simon Tate, David T. MacPherson, Charles Large, Christopher A Hinckley, Joanne Palmer
Publikováno v:
ACS Med Chem Lett
[Image: see text] Drugs that block voltage-gated sodium channels (Na(V)s) have utility in treating conditions including pain, epilepsy, and cardiac arrhythmias and as anesthetics (Lancet Neurol.2010941342420298965; Expert Opin. Ther. Pat.201020755779